In the first of a two-part article, Colin McCall discusses the role of intellectual property rights in corporate transactions within the life sciences industry, explaining how they can help to ensure that the innovations at the centre of a life sciences business provide a return for those making an investment and others depending on the success of the business.
A legal toolkit for life sciences companies and their investors providing access to information on:
Chris Benson and Jocelyn Clarke report on a dispute concerning the acronym used in the BGW Federal Association of Health Industry trade mark...read more
Tim Worden, Debbie Heywood and Paul England discuss the regulatory implications of the latest developments in 'digital medicine'...read more
Verena Bertram discusses the Nagaya Protocol and its implementation in the EU...read more
Verena Bertram discusses the Nagaya Protocol and its implementation in Germany...read more
Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector...